HDAC9 and breast cancer: The HDAC inhibitor romidepsin is being evaluated in association with nivolumab and cisplatin in TNBC (NCT02393794), while the DNMT inhibitor decitabine in combination with pembrolizumab, followed by standard neoadjuvant chemotherapy, is under evaluation for locally advanced HER2− BC (NCT02957968).